Prospective comparison of the IPSS, MIPSS and VPSS questionnaires with uroflowmetry and cognitive functions control in men with benign prostatic hyperplasia

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Introduction. Accurate assessment of lower urinary tract symptoms (LUTS) in patients with benign prostatic hyperplasia (BPH) is one of the key tasks of a urologist for selecting adequate therapy, monitoring treatment, and determining indications for surgical treatment. The International Prostate Symptom Score (IPSS) questionnaire, developed in 1992, has become a simple and widely used method to grade the presence, type, and severity of LUTS in men with BPH. However, the IPSS has certain limitations: the poorer a patient’s cognitive abilities, the greater the likelihood of incorrect responses due to the complexity and abstract nature of the questions and the difficulty in translating subjective sensations into a written numerical score.

In 2011, a new tool, namely the Visual Prostate Symptom Score (VPSS), was proposed as a visual analogue of the IPSS, in which the questions are presented in pictorial form, thereby reducing the dependence on literacy and cognitive function. Despite these advances, the search for the most rational and cognitively accessible questionnaire for assessing LUTS remains relevant.

Aim. To compare the IPSS, modified IPSS (mIPSS), and VPSS questionnaires in men with BPH, with reference to uroflowmetry and cognitive function, and to improve the diagnostic accuracy of IPSS through its modification.

Materials and Methods. A total of 72 men with symptomatic BPH presenting for initial outpatient evaluation were included in the prospective study. The median age was 68 [64–72] years. All patients underwent standard assessments according to the Russian Society of Urology clinical guidelines: urinalysis, complete blood count, prostate-specific antigen (PSA) testing, transrectal ultrasound (TRUS) with measurement of prostate volume and post-void residual urine, renal ultrasonography, and uroflowmetry. Inclusion criteria were: prostate volume 40–180 cc, residual urine ≤150 mL, and PSA < 4 ng/mL. Exclusion criteria were suspicion of prostate cancer or other causes of voiding dysfunction unrelated to BPH.

All patients provided written informed consent, and the study was approved by the local ethics committee. Each participant completed four questionnaires, including the newly developed modified IPSS (mIPSS). In this version, the IPSS items were divided into two groups: voiding (obstructive) symptoms: questions 1, 3, 5, 6; storage (irritative) symptoms: questions 2, 4, 7.

Results. For most questions, the proportion of identical responses between questionnaires exceeded 50%, and all correlation coefficients were r > 0.6, indicating a strong association between the results and suggesting that the tools measure similar constructs and are largely interchangeable. Uroflowmetry parameters correlated significantly only with the total mIPSS score. Both Qmax and Qave showed a significant inverse correlation with mIPSS total score, while voided volume showed no correlation with any questionnaire scores. The urinary stream strength item correlated significantly with Qmax and Qave, and nocturia correlated with all three parameters (Qmax, Qave, and voided volume). This indicates that the mIPSS questionnaire can be used as a rational and sufficiently quick tool for assessing lower urinary tract symptoms (LUTS).

The mIPSS and IPSS questionnaires are interchangeable in terms of the evaluated characteristics of urination; however, mIPSS shows a stronger correlation with objective uroflowmetry parameters and is therefore considered a more reliable assessment method.

Conclusion. The results demonstrate the advantages of the modified IPSS (mIPSS) compared with the standard IPSS, owing to its stronger correlation with objective urodynamic findings and greater ease of use. The mIPSS and VPSS questionnaires may be effectively applied to identify voiding disorders, particularly in patients with cognitive impairment. At the same time, the interchangeability of the questionnaire items and the rationale for dividing the questions into obstructive and irritative categories by splitting them into two columns have been demonstrated.

Full Text

Restricted Access

About the authors

Mikhail E. Efremov

Regional Clinical Hospital No. 1 named after Prof. S.V. Ochapovsky; Kuban State Medical University, Ministry of Health of the Russian Federation

Author for correspondence.
Email: efremov.uro@yandex.ru
ORCID iD: 0000-0003-2733-0619

Сand.Sc.(Med), Assist. of the urology Dept. of the Kuban State Medical University of the Ministry of Health of the Russian Federation; urologist of the Research Institute – Regional Clinical Hospital №1 Prof. S.V. Ochapovsky

Russian Federation, Krasnodar; Krasnodar

Vladimir L. Medvedev

Regional Clinical Hospital No. 1 named after Prof. S.V. Ochapovsky; Kuban State Medical University, Ministry of Health of the Russian Federation

Email: medvedev_vl@mail.ru
ORCID iD: 0000-0001-8335-2578

Dr.Sc. (Med.), PhD, DMS, Full Professor; Head, Dept. of Urology, Kuban State Medical University; Chief, Urology and Nephrology Center, Deputy Chief Physician for Urology, Research Institute – Regional Clinical Hospital №1 Prof. S.V. Ochapovsky

Russian Federation, Krasnodar; Krasnodar

Anatoly D. Anosov

Regional Clinical Hospital No. 1 named after Prof. S.V. Ochapovsky; Kuban State Medical University, Ministry of Health of the Russian Federation

Email: vester.orient@gmail.com
ORCID iD: 0009-0002-2126-3136

first year Postgrad. Student of the Dept. of Urology of the Kuban State Medical University of the Ministry of Health of the Russian Federation, urologist of the Research Institute – Regional Clinical Hospital №1 Prof. S.V. Ochapovsky

Russian Federation, Krasnodar; Krasnodar

Dmitry P. Akopov

Regional Clinical Hospital No. 1 named after Prof. S.V. Ochapovsky; Kuban State Medical University, Ministry of Health of the Russian Federation

Email: akopov-mitya@mail.ru
ORCID iD: 0009-0006-3649-6337

Assist. of the urology Dept. of the Kuban State Medical University of the Ministry of Health of the Russian Federation; urologist of the Research Institute – Regional Clinical Hospital №1 Prof. S.V. Ochapovsky

Russian Federation, Krasnodar; Krasnodar

Mikhail I. Kogan

Rostov State Medical University, Ministry of Health of the Russian Federation

Email: dept_kogan@mail.ru
ORCID iD: 0000-0002-1710-0169

MD., Dr.Sc.(Med), Full Prof., Honored Scientist of the Russian Federation; Head, Dept. of Urology, Pediatric Urology and Reproductive Health

Russian Federation, Rostov-on-Don

Dmitry Sizyakin

Rostov State Medical University, Ministry of Health of the Russian Federation

Email: center@gb-1.ru
ORCID iD: 0000-0001-7125-1374

MD., Dr.Sc.(Med), Full Prof., Honored Doctor of the Russian Federation; Head, Dept. of Urology, Pediatric Urology and Reproductive Health

Russian Federation, Rostov-on-Don

References

  1. Barry MJ, Fowler FJ Jr, O’leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett AT; Measurement Committee of the American Urological Association. The American Urological Association Symptom Index for Benign Prostatic Hyperplasia. J Urol. 2017 Feb;197(2S):S189-S197. doi: 10.1016/j.juro.2016.10.071. Epub 2016 Dec 22. PMID: 28012747.
  2. Lerner LB, McVary KT, Barry MJ, Bixler BR, Dahm P, Das AK et al. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE PART I – Initial Work-up and Medical Management. Journal of Urology [Internet]. 2021 Oct 1 [cited 2025 Mar 3];206(4):806–17. Available from: https://doi.org/10.1097/JU.0000000000002183
  3. Netto Júnior NR, de Lima ML. The influence of patient education level on the International Prostatic Symptom Score. J Urol. 1995 Jul;154(1):97-9. doi: 10.1097/00005392-199507000-00034. PMID: 7539870.
  4. MacDiarmid SA, Goodson TC, Holmes TM, Martin PR, Doyle RB. An assessment of the comprehension of the American Urological Association Symptom Index. J Urol. 1998 Mar;159(3):873-4. PMID: 9474172.
  5. Schlatmann FWM, van Balken MR, de Winter AF, de Jong IJ, Jansen CJM. How Do Patients Understand Questions about Lower Urinary Tract Symptoms? A Qualitative Study of Problems in Completing Urological Questionnaires. Int J Environ Res Public Health. 2022 Aug 5;19(15):9650. doi: 10.3390/ijerph19159650. PMID: 35955002; PMCID: PMC9368298.
  6. Kotelnikova A.V., Pogonchenkova I.V., Kostenko E.V., Petrova L.V., Khaustova A.V. Psychometric validation of screening methods for diagnosing cognitive status in a sample of patients who have suffered an ischemic stroke. Bulletin of Restorative Medicine. 2023;22(2):32-41. https://doi.org/10.38025/2078-1962-2023-22-2-32-41. Russian (Котельникова А.В., Погонченкова И.В., Костенко Е.В., Петрова Л.В., Хаустова А.В. Психометрическая апробация скрининговых методик диагностики когнитивного статуса на выборке пациентов, перенесших ишемический инсульт. Вестник восстановительной медицины. 2023;22(2):32-41. https://doi.org/10.38025/2078-1962-2023-22-2-32-41.
  7. Sandhu JS, Bixler BR, Dahm P et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA Guideline amendment 2023. J Urol. 2023;10.1097/JU.0000000000003698. https://doi.org/10.1097/JU.0000000000003698).
  8. EAU Guidelines. Edn. presented at the EAU Annual Congress Milan 2023. Management of Non-neurogenic Male. ISBN 978-94-92671-19-6. LUTS
  9. Clinical guidelines of the Russian Society of Urology «Benign Prostatic Hyperplasia» Ministry of Health of the Russian Federation. 2024. Russian (Клинические рекомендации РОУ «Доброкачественная гиперплазия предстательной железы». МЗ РФ. 2024 г.).
  10. van der Walt CL, Heyns CF, Groeneveld AE, Edlin RS, van Vuuren SP. Prospective comparison of a new visual prostate symptom score versus the international prostate symptom score in men with lower urinary tract symptoms. Urology. 2011 Jul;78(1):17-20. doi: 10.1016/j.urology.2011.01.065. Epub 2011 May 7. PMID: 21550646.
  11. Heyns CF, van der Walt CL, Groeneveld AE. Correlation between a new visual prostate symptom score (VPSS) and uroflowmetry parameters in men with lower urinary tract symptoms. S Afr Med J. 2012 Mar 7;102(4):237-40. PMID: 22464506.
  12. Taneja Y, Ram P, Kumar S, Raj K, Singh CK, Dhaked SK, Jaipuria J. Comparison of Visual Prostate Symptom Score and International Prostate Symptom Score in the evaluation of men with benign prostatic hyperplasia: A prospective study from an Indian population. Prostate Int. 2017 Dec;5(4):158-161. doi: 10.1016/j.prnil.2017.04.004. Epub 2017 Apr 22. PMID: 29188203; PMCID: PMC5693472.
  13. Lopes MHBM, D’Ancona CAL, Moretti TBC, Higa R, Victal ML, Camisão AR, Braga DA, Reis LO. Validation of Visual Prostate Symptom Score (VPSS) in Brazilian Sample Population. J Wound Ostomy Continence Nurs. 2023 Jul-Aug 01;50(4):326-330. doi: 10.1097/WON.0000000000000996. PMID: 37467413.
  14. Dudarev V.A. Improvement of Diagnostics and Treatment of Urinary Disorders in Prostatic Hyperplasia in Elderly Men. Diss. for the degree of Candidate of Medical Sciences, 2024. Russian (Дударев В.А. Совершенствование диагностики и лечения нарушений мочеиспускания при гиперплазии предстательной железы у мужчин пожилого возраста. Дисс. на соискание ученой степени к.м.н., 2024 г.).
  15. Chatterjee S, Kumar A, Pal DK. Study of correlation between Visual Prostate Symptom Score and International Prostate Symptom Score in men with lower urinary tract symptoms with reference to Uroflowmetry parameters in Indian population. Urologia. 2023 May;90(2):377-380. doi: 10.1177/03915603231157573. Epub 2023 Mar 8. PMID: 36883382.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2025 Bionika Media